Business Wire

CRO Industry Veteran John Potthoff Joins SynteractHCR Board of Directors

Del

SynteractHCR, a leading full-service contract research organization (CRO), announced the appointment of industry veteran John Potthoff to its Board of Directors, effective immediately. Potthoff draws on extensive operational, business development and leadership experience derived through his 25-year career dedicated to clinical development.

Potthoff is a founder and CEO of Elligo Health Research, a leading clinical research infrastructure provider whose mission is to redefine the clinical trial process. Prior to this, he served as CEO of Theorem Clinical Research and COO of INC Research, having successfully contributed to the impressive growth of both CROs. In 2000 he founded and was CEO of Tanistry, a CNS focused CRO, which was acquired by INC Research. He currently sits on the Board of Directors for Chesapeake IRB and previously served as a member of the Board of Directors for Chiltern.

“I have had the pleasure of working directly with John in the past. He is both a respected business leader and an experienced board member in our industry,” said Steve Powell, CEO of SynteractHCR. “Drawing on his years of experience as a CRO executive, industry leader and now CEO of a company that implements new approaches to clinical trial conduct, John will provide fresh insights and counsel invaluable to SynteractHCR and our customers. I am delighted John has agreed to join our Board.”

"We have known John for over 10 years and have seen how he has played a leadership role in building value at INC Research and Theorem," added Ramsey Frank, partner and co-founder of Amulet Capital. "We welcome John’s addition to the board and are confident his industry acumen will help us build on SynteractHCR’s leading market position and continue to advance the company’s success.”

About SynteractHCR

With 800 staff members across 21 countries, SynteractHCR is an international full-service contract research organization with a successful three-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 60 countries, offering broad therapeutic expertise, with notable depth in oncology, immunotherapy, CNS and infectious disease, among other indications. With its “Shared Work – Shared Vision” philosophy, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

Contact information

For SynteractHCR
Nikki Sachman, 760-230-2424
nikki@clearpointagency.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

The Indian Detective, Starring Russell Peters, Premieres Tuesday, December 19, 2017 on Netflix Worldwide20.11.2017 16:00Pressemelding

Full release here. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005203/en/ (Photo: Business Wire) Following today’s announcement by Netflix, THE INDIAN DETECTIVE , a four-part comedy-drama series starring international comedy sensation Russell Peters, award-winning actor Anupam Kher (The Big Sick, Silver Linings Playbook), the iconic William Shatner (Star Trek), Christina Cole (Suits, Casino Royale), Hamza Haq (mother!, Bon Cop, Bad Cop 2), Akshay Kumar (Star Wars Ep VIII), Meren Reddy (Madiba, Homeland) and Mishqah Parthiephal (Keeping Up with the Kandasamys, Snake Park), will premiere on December 19, 2017 on Netflix worldwide, following an initial run on CTV Canada in November.

Andersen Global Expands Presence in Italy with New Location in Venice-Mestre, on the Venetian Mainland20.11.2017 14:30Pressemelding

Andersen Global is proud to announce a new presence in Venice-Mestre, on the Venetian mainland in Italy through the expansion of Italian member firm, Andersen Tax & Legal. In addition, the Milan office will relocate at the end of November. The new office in Mestre and new location in Milan have been established to better serve the growing client base in Italy. Andersen Tax & Legal now has six locations in Italy: Milan, Brescia, Rome, Venice, Mestre, and Monza. Andrea De Vecchi, Office Managing Partner of Andersen Tax & Legal in Italy, and Regional Managing Partner in Europe shared, “Our new location in Venice-Mestre and expanded presence in Milan allow us to better serve our clients and continue to build our capabilities within the region. Through this expansion, we are able to reach new markets and also improve the quality of life for our employees.” Venice-Mestre is a sign

NexPlayer HTML5 Player Fully Compatible with Conviva across All Browsers and Devices20.11.2017 14:00Pressemelding

NexStreaming, the provider of NexPlayer SDK, the market leader player SDK for OTT apps, announced today that the NexPlayer HTML5 player is fully compatible with Conviva Video AI Platform. This pre-integrated solution brings great value to video services: from now on, they will be able to enable the highest quality HLS & DASH live streaming across all browsers and devices with NexPlayer, and ensure an outstanding user experience with accurate analytics about the quality of the video experience thanks to Conviva. In this technology integration, NexPlayer HTML5 is fully optimized with Conviva’s QoE analytics. NexPlayer sends information regarding the use of the HTML5 based OTT service, including when the user pauses the video or the video is buffering as well as information about the frame-rate. Conviva measures and analyzes this information so that video service providers and publishers

AGCO’s Innovation Rewarded with Prestigious Awards at Agritechnica 201720.11.2017 14:00Pressemelding

AGCO, Your Agriculture Company, (NYSE:AGCO), a worldwide manufacturer and distributor of agricultural equipment and solutions, achieved remarkable success with 17 major awards at the prestigious Agritechnica 2017 event in Hannover, Germany. As a result of the votes cast by an independent expert committee, AGCO was once again one of the most successful manufacturers at Agritechnica 2017 by way of the number of innovation awards received. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005614/en/ The new Fendt Track Tractor 943 Vario MT won the treasured award "Machine of the Year 2018" in the Category XXL Tractors (Photo: Business Wire) “Winning these significant awards is a testament to our continued commitment to deliver high-tech solutions for farmers feeding the world,” said Martin Richenhagen

Leading Broker ActivTrades Wins Le Fonti Forex Broker of the Year Award for the Second Time20.11.2017 13:30Pressemelding

ActivTrades, one of the world’s leading online Forex Brokers, has won the Le Fonti Forex Broker of the Year Award for the second year running. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171120005576/en/ ActivTrades was awarded at the Le Fonti Awards (Photo: Business Wire) A UK-regulated firm with offices in Europe and the Middle East, ActivTrades was selected as the winner by the editorial staff of over 120 journalists at Le Fonti, the international and independent media company and research centre. Le Fonti credited the broker for “aiming to maximise its clients’ trading through a unique mix of superior value proposition, diverse product offering and stellar customer service”. Le Fonti’s judges added that ActivTrades offers “some of the tightest spreads in the industry” a

European Commission Extends License for Janssen’s ZYTIGA® Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients20.11.2017 13:30Pressemelding

Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has granted approval to broaden the existing marketing authorisation for ZYTIGA® (abiraterone acetate) plus prednisone / prednisolone to include an earlier stage of metastatic prostate cancer than its current indications. Abiraterone acetate plus prednisone / prednisolone can now be used for the treatment of newly-diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).1 “Prostate cancer is the most common form of cancer in men throughout Europe and today’s decision helps to fill a critical medical need for these patients. We hope to significantly improve the lives of many men across Europe living with this disease and the approval of this treatment in an earlier stage of prostate cancer helps address this,”

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom